Publications by authors named "Baransel Kamaz"
Approximately 25% of patients with essential thrombocythemia (ET) present with extreme thrombocytosis (ExT), defined as having a platelet count ≥1000 × 109/L. ExT patients may have an increased bleeding risk associated with acquired von Willebrand syndrome. We retrospectively analyzed the risk of bleeding and thrombosis in ExT vs non-ExT patients with ET at Dana-Farber Cancer Institute and Massachusetts General Hospital from 2014 to 2022 to inform treatment decisions.
View Article and Find Full Text PDFArticle Synopsis
- Most JAK2-negative myeloproliferative neoplasms (MPNs) have mutations in calreticulin (CALR), which produce unique neoantigens that could be useful for cancer vaccines, but CALR-specific T cells are surprisingly rare in these patients.
- Research found that patients with CALR MPN lack MHC-I alleles that effectively present CALR neoepitopes, possibly preventing immune responses that could have led to earlier tumor rejection.
- The study suggests that using modified CALR heteroclitic peptide vaccines tailored to the MHC-I alleles of patients can effectively stimulate an immune response, indicating their potential as a new therapeutic approach for CALR MPN.
Article Synopsis
- The JAK2-V617F mutation is a leading cause of myeloproliferative neoplasms, which are conditions that lead to an overproduction of blood cells.
- Research shows that this mutation promotes the expansion of myeloid blood cells and increases the production of white blood cells, red blood cells, and platelets.
- A study using single-cell RNA sequencing revealed that the mutation enhances the expression of certain immune-related genes and proteins in bone marrow progenitor and monocyte cells, indicating its specific effects on blood cell development.
Some cancers originate from a single mutation event in a single cell. Blood cancers known as myeloproliferative neoplasms (MPNs) are thought to originate when a driver mutation is acquired by a hematopoietic stem cell (HSC). However, when the mutation first occurs in individuals and how it affects the behavior of HSCs in their native context is not known.
View Article and Find Full Text PDFPatients with immune deficiencies from cancers and associated treatments represent a growing population within the intensive care unit with increased risk of morbidity and mortality from sepsis. Mesenchymal stromal cells (MSCs) are an integral part of the hematopoietic niche and express toll-like receptors, making them candidate cells to sense and translate pathogenic signals into an innate immune response. In this study, we demonstrate that MSCs administered therapeutically in a murine model of radiation-associated neutropenia have dual actions to confer a survival benefit in Pseudomonas aeruginosa pneumo-sepsis that is not from improved bacterial clearance.
View Article and Find Full Text PDF